PAR3 Inhibitors as Therapeutic for Pain

Technology #ua16-176

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Josef Vagner
Associate Research Professor, BIO5 Institute
Scott Boitano
Professor, Physiology
Theodore Price
Associate Professor
Gregory Dussor
Assistant Professor, Pharmacology
Managed By
Rakhi Gibbons
Asst. Director, Life Sciences (520) 626-6695

Title: PAR3 Inhibitors as Therapeutic for Pain

 

Invention: The technology identifies protease activated receptor-3 (PAR3) and PAR3 inhibitors as a novel target for the treatment of pain.

Background: Pain is one of the most common reasons in which individuals seek medical attention. Globally, pain affects at least 1.5 billion people, with the incidence rate increasing complementary to age. Current treatments for chronic pain can be harmful to patients in that there is a history of abuse accompanied by intolerable side effects. This technology has the potential to represent a first-in-class therapy for pain once the technology is determined safe and efficient at mitigating pain.

 

Applications:

  • Pain therapeutics
  • Mitigation of periodontitis
  • Potential for application in cancer 

 

Advantages:

  • Potential to represent a first-in-class therapy for pain once the technology is determined safe and efficient at mitigating pain

Licensing Manager: 

Rakhi Gibbons

RakhiG@tla.arizona.edu

(520) 626-6695